Dasatinib: ten years of clinical practice worldwide
The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are presented. The dasatinib and imatinib compara...
Saved in:
Main Authors: | K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2016-03-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/178 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01) -
Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01) -
Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01) -
Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
by: Ana Maria Meireles, et al.
Published: (2025-07-01)